June 2026
Proprietary AI analyst is now available
Largest Medical Imaging & Diagnostics Public Companies in Sweden
Benchmark revenue and EBITDA valuation multiples for public comps like
Vimian Group, RaySearch Labs, Devyser Diagnostics, INIFY Laboratories and ContextVision.
 | Vimian Group AB specializes in the areas of animal health, such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world. | $3 | -30% | $2B | $2B | 3.6x | 13.5x | ||
| RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops advanced software solutions for improved cancer treatment. The company develops and markets the RayStation* treatment planning system and RayCare* oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of Sweden, North America, Asia Pacific, Europe and the rest of the world. | $24 | -34% | $822M | $815M | 5.4x | 12.4x | ||
| Devyser Diagnostics AB is engaged in the development, manufacture, and sale of kits for genetic testing in routine diagnostic laboratories. The products are used for advanced genetic testing in the hereditary disease, oncology, and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. | $10 | -26% | $171M | $168M | 6.0x | 57.3x | ||
| INIFY Laboratories AB provides cancer diagnostics through ultra-modern laboratory services within pathology. It uses a fully digital, standardized, and AI-supported workflow to optimize quality and response times, initially within the prostate. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer’s organization. | $1 | -19% | $58M | $56M | 24.0x | (8.4x) | ||
| ContextVision AB is a medical technology company. It develops and sells image enhancement software for medical diagnosis and artificial intelligence. Its product portfolio includes image enhancement software for 2D/3D/4D (dimensional) ultrasound, magnetic resonance imaging (MRI), X-Ray, radiography, and mammography. its geographical segments are Asia, Europe, and America. | $0 | -25% | $28M | $22M | 1.7x | 9.1x | ||
| SenzaGen AB markets sells, and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its laboratory and licensed Contract Research Organizations (CROs) in Sweden. It offers animal-free testing of chemical compounds in cosmetics, pharmaceuticals, food products, and dyes. It operates in five market segments- Cosmetics, Chemicals, Medical devices, Pharmaceuticals, and Nutrition/food additives. The majority is from the Pharmaceuticals segment. Geographically it operates in North America, Europe, APAC, and RoW, the majority is from Europe. | $1 | +1% | $19M | $17M | 2.7x | (18.7x) | ||
| Immunovia AB molecular diagnostic company. It develops and commercializes diagnostic tools for complex forms of cancer and autoimmune diseases. Its technology platform IMMray (TM), is based on antibody microarray analysis. The company is currently developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. | $0 | -39% | $14M | $8M | 73.7x | (0.9x) | ||
| Synthetic MR AB develops software solutions for Magnetic Resonance Imaging that support shorter exam times and deliver more information to the clinician. Its product is available in different packages. SyMRI IMAGE provides high MRI workflows and enables automatic segmentation of brain tissue, providing objective decision support, MAGiC is a customer-specific version of SyMRI IMAGE marketed and sold by GE Healthcare under a license agreement, SyMRI NEURO includes contrast images, biomarker segmentation, volumetric measurements of brain tissues and quantitative parametric maps, and SyMRI Research Edition includes contrast images, volumetric measurements and quantitative maps to provide more information to the researcher. | $0 | -75% | $8M | $4M | 0.7x | (1.4x) | ||
| Spermosens AB is developing a revolutionary platform technology for diagnosing male-factor infertility and directing to the right infertility treatment. It is a developer of medical device products for male infertility, individualizing In Vitro Fertilization (IVF) diagnostics and treatment creating a new standard for faster and safer IVF treatments. | $0 | +11% | $3M | $3M | - | (2.7x) | ||
| Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector. | $0 | -57% | $3M | $2M | 38.0x | (0.6x) | ||
| Level Bio AB is a parent company and operates through subsidiary. It develops and manufactures diagnostic kits for the clinical market and also is a distributor and full service partner to molecular biology labs in the Nordics. | $0 | -16% | $2M | $2M | 0.6x | (15.1x) | ||
| NanoEcho AB (publ) is a Swedish medical technology company. The company is developing a new diagnostic method to track rectal cancer's effect on nearby lymph nodes for the generation of health economic gains. The company's imaging technology is based on a new medical method where nanotechnology is combined with modern ultrasound technology to improve diagnosis methods. | $0 | -49% | $2M | $2M | 35.7x | (1.2x) | ||
| Attana AB offers biologically relevant information to improve efficiency and performance of pharmaceutical drug development. | $0 | -73% | $1M | $1M | 5.2x | (1.5x) | ||
| Lumito AB is a Swedish company that specializes in the medical research and development of imaging technology for use in digital pathology. It has developed the next-generation tissue analysis system, based on upconverting nanoparticles (UCNPs). Lumito SCIZYS is a cutting-edge, high-sensitivity system combining labeling and imaging technologies to locate and measure biomarkers in tissue samples. The company holds a broad patent portfolio of three patent families. Lumito’s solution enables quantitative and objective assessment of tissue samples, addressing a multitude of challenges in drug development and academic research. | $0 | -98% | $641K | ($16K) | - | 0.0x | ||
| Median | $0 | -32% | $11M | $6M | 5.3x | (1.1x) |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.